| Bioactivity | Norleual, an angiotensin (Ang) IV analog, is a hepatocyte growth factor (HGF)/c-Met inhibitor with an IC50 of 3 pM. Norleual is an AT4 receptor antagonist and exhibits potent antiangiogenic activities[1]. |
| Invitro | Norleual at 20 and 50 pM significantly reduces HGF-dependent c-Met and Gab1 phosphorylation. 20 pM Norleual dramatically reduces HGF-initiated association between Gab1 and c-Met in HEK293 cells. Norleual markedly attenuates HGF-dependent c-Met activation and downstream signaling[1].Norleual (1 pM-1 μM; 4 days) is able to inhibit HGF-dependent signaling, proliferation, migration, and invasion in multiple cell types at concentrations in the picomolar range in MDCK cells[1]. |
| Name | Norleual |
| CAS | 334994-34-2 |
| Shortening | {Nle}-Y-{Leu-(CH2-NH2)}-HPF |
| Formula | C41H58N8O7 |
| Molar Mass | 774.95 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
Norleual
CAS: 334994-34-2 F: C41H58N8O7 W: 774.95
Norleual, an angiotensin (Ang) IV analog, is a hepatocyte growth factor (HGF)/c-Met inhibitor with an IC50 of 3 pM. Norl
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.